久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Aptamer and WuXi AppTec Form Research Partnership contractpharma
    July 23, 2021
    ?Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, have entered a research collaboration to identify new Optimer-enabled therapeutics.
  • Aptamer Group Collaborates with PinotBio contractpharma
    June 03, 2021
    ?Aptamer Group Limited, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for ...
  • Aptamer Extends Collaboration with AstraZeneca contractpharma
    March 08, 2021
    Aptamer Group, the developer of Optimer reagents and therapeutics, has extended their current agreement with AstraZeneca.
  • Aptamer Group, AstraZeneca extend collaboration to explore next-gen drug delivery approaches expresspharma
    March 05, 2021
    The companies will evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.
PharmaSources Customer Service